Eli Lilly and Company $LLY Shares Purchased by Delta Wealth Advisors LLC

Delta Wealth Advisors LLC lifted its stake in Eli Lilly and Company (NYSE:LLY) by 351.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,751 shares of the company’s stock after purchasing an additional 3,699 shares during the quarter. Eli Lilly and Company comprises about 3.3% of Delta Wealth Advisors LLC’s portfolio, making the stock its 13th largest holding. Delta Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $4,370,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. Piedmont Capital Management LLC NC grew its position in Eli Lilly and Company by 3.7% during the 1st quarter. Piedmont Capital Management LLC NC now owns 892 shares of the company’s stock worth $820,000 after purchasing an additional 32 shares during the last quarter. Stokes Capital Advisors LLC increased its stake in Eli Lilly and Company by 687.7% during the 1st quarter. Stokes Capital Advisors LLC now owns 6,286 shares of the company’s stock valued at $5,782,000 after purchasing an additional 5,488 shares in the last quarter. Pacific Sage Partners LLC increased its stake in Eli Lilly and Company by 15.8% during the 1st quarter. Pacific Sage Partners LLC now owns 1,524 shares of the company’s stock valued at $1,402,000 after purchasing an additional 208 shares in the last quarter. Parker Financial LLC purchased a new position in shares of Eli Lilly and Company in the first quarter worth $201,000. Finally, Xcel Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 3.2% in the first quarter. Xcel Wealth Management LLC now owns 388 shares of the company’s stock worth $357,000 after buying an additional 12 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 7.0%

NYSE:LLY opened at $1,206.51 on Friday. The firm has a market capitalization of $1.14 trillion, a P/E ratio of 42.86, a PEG ratio of 1.32 and a beta of 0.53. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,215.76. The company’s fifty day moving average price is $1,036.28 and its 200-day moving average price is $1,020.95. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the company posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on LLY. Royal Bank Of Canada reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, May 21st. Rothschild & Co Redburn raised their target price on Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $1,285.00 price target on shares of Eli Lilly and Company in a research report on Friday, March 6th. The Goldman Sachs Group reiterated a “buy” rating and set a $1,283.00 price target on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Finally, HSBC lowered Eli Lilly and Company from a “hold” rating to a “reduce” rating and cut their price objective for the company from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $1,235.07.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia across all lines of therapy, which could expand Lilly’s oncology revenue opportunity in the EU. Article Title
• Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with new details on the Medicare GLP-1 Bridge program that could broaden access to Foundayo (orforglipron) and Zepbound for eligible Medicare Part D patients starting July 1. Article Title
• Positive Sentiment: Management’s expanded access push and continued clinical progress in obesity/diabetes are reinforcing the view that Lilly remains a leader in the weight-loss drug race, supporting bullish sentiment. Article Title
• Neutral Sentiment: Some recent coverage highlights Lilly’s strong pipeline and market leadership, but also notes valuation concerns and a less attractive entry point after the stock’s big run. Article Title
• Neutral Sentiment: News about Lilly launching its cancer drug Tanstrive in India adds another growth angle, but it appears to be a smaller near-term stock driver than the obesity and EU approval updates. Article Title

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.